SCHEMBL30983534

SCHEMBL30983534

CC1(Oc2ncnc3c2nc(-c2ccc(OCC(=O)N4CCNCC4)cc2Cl)n3Cc2ccccc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR183 P32249 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ RECQL P46063 1/20 0.38
▸ GHSR Q92847 1/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ TPSAB1 Q15661 1/20 0.36
▸ TPSD1 Q9BZJ3 1/20 0.36
▸ TPSG1 Q9NRR2 1/20 0.36
▸ SCN7A Q01118 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ ALK Q9UM73 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983424 0.92 HTR1D (0.43) GPR183ALDH1A1MEN1KMT2AKDM4E
SCHEMBL30983954 0.89 PLA2G2A (0.39) KMT2AKDM4ECNR1PIK3CD
SCHEMBL30983425 0.88 PIK3CD (0.38) ALDH1A1MEN1KMT2ASMN1; SMN2PIK3CD
SCHEMBL30983924 0.87 PLA2G2A (0.38) KMT2ACNR1PIK3CD
SCHEMBL30983795 0.86 PDE2A (0.42) ALDH1A1KDM4EPIK3CDALKHTR6
SCHEMBL30983502 0.86 NPC1 (0.38) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL30983512 0.86 KMT2A (0.36) MEN1KMT2ASMN1; SMN2CNR1PIK3CD
SCHEMBL30984034 0.86 PIK3CD (0.37) ALDH1A1MEN1KMT2AKDM4ECNR1
SCHEMBL30983420 0.85 HRH4 (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2PIK3CD
SCHEMBL31321975 0.84 HTR6 (0.42) CNR1PIK3CDMAPTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB GPR183 3014/4885ALDH1A1 3824/4885MEN1 3755/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB GPR183 3014/4885ALDH1A1 3824/4885MEN1 3755/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB GPR183 3014/4885ALDH1A1 3824/4885MEN1 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback